Compare HLN & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLN | GMAB |
|---|---|---|
| Founded | 2022 | 1999 |
| Country | United Kingdom | Denmark |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.5B | 31.9B |
| IPO Year | 2021 | 2008 |
| Metric | HLN | GMAB |
|---|---|---|
| Price | $9.19 | $51.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $10.40 | ★ $65.01 |
| AVG Volume (30 Days) | ★ 22.5M | 6.3M |
| Earning Date | 07-30-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.35 | $27.61 |
| Revenue Next Year | $3.29 | $21.18 |
| P/E Ratio | $49.05 | ★ $1.90 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.38 | $23.62 |
| 52 Week High | $11.28 | $59.97 |
| Indicator | HLN | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 47.60 | 59.86 |
| Support Level | $9.08 | $25.91 |
| Resistance Level | $9.32 | $59.97 |
| Average True Range (ATR) | 0.19 | 3.02 |
| MACD | -0.01 | -0.70 |
| Stochastic Oscillator | 48.33 | 47.44 |
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.